Skip to main content

Dr. Trevor Feinstein, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
23
In the NPI registry since
2007
Medicare patients seen, 2024
760

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2003Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    GA license 65768

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
760
Services billed
254,069
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram36,36014
Injection, oxaliplatin, 0.5 mg18,86617
Injection, pembrolizumab, 1 mg15,20025
Injection, denosumab, 1 mg12,48070
Injection, paclitaxel, 1 mg9,12814
Injection, ferric derisomaltose, 10 mg5,30047
Injection, dexamethasone sodium phosphate, 1 mg3,05474
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg2,99711
Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg2,00711
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count1,509641

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 20 companies reported 105 payments worth $94,610 in total to this clinician.

By type
Compensation for services other than consulting (speaking, faculty)$66,057
Consulting Fee$12,596
Travel and Lodging$7,062
Honoraria$5,880
Food and Beverage$3,015

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$8,567
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$8,238
Jul 17, 2025Genzyme Corporation
Jul 17, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$6,920
May 9, 2025Recordati_rare_diseases_inc.
May 9, 2025
Honoraria
ENJAYMO · HEMATOLOGY
$5,880
Sep 13, 2025Genzyme Corporation
Sep 13, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$5,272
Nov 10, 2025AstraZeneca Pharmaceuticals LP
Nov 10, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$4,690
Aug 6, 2025AstraZeneca Pharmaceuticals LP
Aug 6, 2025
Consulting Fee$4,355
Sep 30, 2025Daiichi Sankyo Inc.
Sep 30, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · ONCOLOGY
$4,020
Sep 3, 2025AstraZeneca Pharmaceuticals LP
Sep 3, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$3,350
Apr 29, 2025AstraZeneca Pharmaceuticals LP
Apr 29, 2025
Compensation for services other than consulting (speaking, faculty)
IMFINZI · Oncology
Company’s descriptionSpeaker Fee
$3,350
All 48 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 17, 2025AstraZeneca Pharmaceuticals LP
Dec 17, 2025
Travel and Lodging
travel to Duluth, GA
$77.00
Dec 16, 2025AstraZeneca Pharmaceuticals LP
Dec 16, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$2,010
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$8,238
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Fort Myers, FL · in-kind
$900
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Fort Myers, FL · in-kind
$567
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Fort Myers, FL · in-kind
$140
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Fort Myers, FL
$46.75
Nov 20, 2025Genzyme Corporation
Nov 20, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Fort Myers, FL
$30.00
Nov 13, 2025AstraZeneca Pharmaceuticals LP
Nov 13, 2025
Travel and Lodging
DATROWAY · Oncology · travel to Alpharetta, GA
$77.00
Nov 10, 2025AstraZeneca Pharmaceuticals LP
Nov 10, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$4,690
Nov 10, 2025AstraZeneca Pharmaceuticals LP
Nov 10, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$2,010
Nov 10, 2025AstraZeneca Pharmaceuticals LP
Nov 10, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$2,010
Nov 6, 2025AstraZeneca Pharmaceuticals LP
Nov 6, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$250
Oct 31, 2025AstraZeneca Pharmaceuticals LP
Oct 31, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$2,010
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$8,567
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$3,295
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Norwood, MA · in-kind
$867
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Norwood, MA · in-kind
$590
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Norwood, MA · in-kind
$298
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Norwood, MA
$60.00
Oct 14, 2025Genzyme Corporation
Oct 14, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Norwood, MA
$23.91
Sep 30, 2025Daiichi Sankyo Inc.
Sep 30, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · ONCOLOGY
$4,020
Sep 26, 2025Recordati_rare_diseases_inc.
Sep 26, 2025
Consulting Fee
ENJAYMO · HEMATOLOGY
$2,205
Sep 25, 2025AstraZeneca Pharmaceuticals LP
Sep 25, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$2,010
Sep 25, 2025Daiichi Sankyo Inc.
Sep 25, 2025
Travel and Lodging
DATROWAY · ONCOLOGY · travel to DULUTH, GA · in-kind
$718
Sep 24, 2025AstraZeneca Pharmaceuticals LP
Sep 24, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$600
Sep 16, 2025AstraZeneca Pharmaceuticals LP
Sep 16, 2025
Consulting Fee$1,340
Sep 13, 2025Genzyme Corporation
Sep 13, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$5,272
Sep 9, 2025Daiichi Sankyo Inc.
Sep 9, 2025
Travel and Lodging
DATROWAY · ONCOLOGY · travel to AUGUSTA, GA · in-kind
$891
Sep 3, 2025AstraZeneca Pharmaceuticals LP
Sep 3, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$3,350
Aug 21, 2025AstraZeneca Pharmaceuticals LP
Aug 21, 2025
Compensation for services other than consulting (speaking, faculty)
DATROWAY · Oncology
Company’s descriptionSpeaker Fee
$600
Aug 6, 2025AstraZeneca Pharmaceuticals LP
Aug 6, 2025
Consulting Fee$4,355
Jul 24, 2025Genzyme Corporation
Jul 24, 2025
Consulting Fee
WAYRILZ · Immunology
$2,016
Jul 17, 2025Genzyme Corporation
Jul 17, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$6,920
Jul 17, 2025Genzyme Corporation
Jul 17, 2025
Travel and Lodging
WAYRILZ · Immunology · travel to Chattanooga, TN · in-kind
$890
Jul 8, 2025Genzyme Corporation
Jul 8, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$2,307
May 9, 2025Recordati_rare_diseases_inc.
May 9, 2025
Honoraria
ENJAYMO · HEMATOLOGY
$5,880
May 9, 2025Recordati_rare_diseases_inc.
May 9, 2025
Travel and Lodging
ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ
$608
May 9, 2025Recordati_rare_diseases_inc.
May 9, 2025
Travel and Lodging
ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ
$193
May 9, 2025Recordati_rare_diseases_inc.
May 9, 2025
Travel and Lodging
ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ
$50.00
May 9, 2025Recordati_rare_diseases_inc.
May 9, 2025
Travel and Lodging
ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ
$35.00
Apr 29, 2025AstraZeneca Pharmaceuticals LP
Apr 29, 2025
Compensation for services other than consulting (speaking, faculty)
IMFINZI · Oncology
Company’s descriptionSpeaker Fee
$3,350
Apr 28, 2025AstraZeneca Pharmaceuticals LP
Apr 28, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$2,680
Apr 1, 2025AstraZeneca Pharmaceuticals LP
Apr 1, 2025
Compensation for services other than consulting (speaking, faculty)
Company’s descriptionSpeaker Fee
$250
Feb 28, 2025Genzyme Corporation
Feb 28, 2025
Compensation for services other than consulting (speaking, faculty)
WAYRILZ · Immunology
$1,318
Feb 13, 2025AstraZeneca Pharmaceuticals LP
Feb 13, 2025
Consulting Fee
DATROWAY · Oncology
$670
Jan 22, 2025AstraZeneca Pharmaceuticals LP
Jan 22, 2025
Consulting Fee
DATROWAY · Oncology
$2,010
Jan 22, 2025AstraZeneca Pharmaceuticals LP
Jan 22, 2025
Compensation for services other than consulting (speaking, faculty)
IMFINZI · Oncology
Company’s descriptionSpeaker Fee
$300

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Georgia →

Industry-funded research

Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $369,999 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
    AstraZeneca Pharmaceuticals LP
  • A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
    Janssen Research & Development, LLC
  • A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treat…
    AstraZeneca Pharmaceuticals LP
  • A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment Wi…
    Genmab A/s
  • A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
    AstraZeneca Pharmaceuticals LP
  • Cold Agglutinin Disease Real World Evidence Registry
    Sanofi US Services Inc. · Active, not recruiting · NCT05791708
  • A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase in…
    AstraZeneca Pharmaceuticals LP
  • A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
    Janssen Research & Development, LLC
  • A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
    AstraZeneca UK Limited
  • Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Fayetteville

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 2, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1457545709. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.